The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care

Area of Science:

• Oncology
• Translational Medicine
• Bioengineering

Background:

• Precision medicine offers tailored cancer treatments, but clinical translation of molecular profiling data remains a challenge.
• Effective management of complex diseases like cancer requires individualized therapeutic strategies.
• Current methods for translating tumor characterization into actionable clinical insights are limited.

Purpose of the Study:

• To introduce the Mouse Hospital as a platform for pre- and co-clinical evaluation of personalized cancer therapies.
• To highlight the integration of patient-derived xenografts (PDX) and genetically engineered mouse models (GEMMs) for disease modeling.
• To demonstrate how the Mouse Hospital can bridge the gap between molecular profiling and clinical application in precision oncology.

Main Methods:

• Utilizing patient-derived xenograft (PDX) models to mimic human tumor responses.
• Employing genetically engineered mouse models (GEMMs) for in situ tumor modeling.
• Integrating the Mouse Hospital infrastructure with co-clinical trials and organoid technologies.

Main Results:

• PDX and GEMM approaches have demonstrated efficacy in modeling human tumor responses.
• Co-Clinical Trials within the Mouse Hospital framework provide insights for individual patient treatment strategies.
• The Mouse Hospital platform facilitates the evaluation of novel therapeutic strategies in a clinically relevant manner.

Conclusions:

• The Mouse Hospital, combined with PDX and GEMM technologies, is crucial for advancing precision medicine in oncology.
• Integrating the Mouse Hospital with organoid technologies enhances its capability to deliver personalized therapeutic approaches.
• This integrated platform enables medical centers to fully leverage the benefits of precision medicine for cancer treatment.